%0 Generic %A L., Zuo %A M., Wang %A F., Hou %A Y., Yan %A N., Chen %A J., Qian %A B., Bieber %A R.L., Pisoni %A B.M., Robinson %D 2016 %T Supplementary Material for: Anemia Management in the China Dialysis Outcomes and Practice Patterns Study %U https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Anemia_Management_in_the_China_Dialysis_Outcomes_and_Practice_Patterns_Study/5129164 %R 10.6084/m9.figshare.5129164.v1 %2 https://karger.figshare.com/ndownloader/files/8717653 %K China %K Domestic erythropoietin stimulating agents %K End-stage renal disease-related anemia %K Intravenous iron %X Background: As the utilization of hemodialysis increases in China, it is critical to examine anemia management. Methods: Using data from the China Dialysis Outcomes and Practice Patterns Study (DOPPS), we describe hemoglobin (Hgb) distribution and anemia-related therapies. Results: Twenty one percent of China's DOPPS patients had Hgb <9 g/dl, compared with ≤10% in Japan and North America. A majority of medical directors targeted Hgb ≥11. Patients who were female, younger, or recently hospitalized had higher odds of Hgb <9; those with insurance coverage or on twice weekly dialysis had lower odds of Hgb <9. Iron use and erythropoietin-stimulating agents (ESAs) dose were modestly higher for patients with Hgb <9 compared with Hgb in the range 10-12. Conclusion: A large proportion of hemodialysis patients in China's DOPPS do not meet the expressed Hgb targets. Less frequent hemodialysis, patient financial contribution, and lack of a substantial increase in ESA dose at lower Hgb concentrations may partially explain this gap. Video Journal Club ‘Cappuccino with Claudio Ronco' at http://www.karger.com/?doi=442741. %I Karger Publishers